Boston Trust Walden Corp Sells 15,695 Shares of Amgen Inc. $AMGN

Key Points

• Boston Trust Walden cut its Amgen stake by 18.9% in the third quarter, selling 15,695 shares and retaining 67,134 shares valued at about $28.3 million.
• Amgen beat quarterly earnings and revenue expectations, with EPS of $6.45 and revenue of $10.37 billion; revenue rose 8.5% year over year. The company declared a quarterly dividend of $2.52 per share, equivalent to a 2.2% yield.
• Analyst views remain mixed: the stock has a consensus “Hold” rating and $419.10 average price target, though some firms raised targets and maintained positive ratings. The article also notes institutional investors own 76.5% of Amgen shares.

Boston Trust Walden Corp trimmed its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 18.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 67,134 shares of the medical research company's stock after selling 15,695 shares during the period. Boston Trust Walden Corp's holdings in Amgen were worth $28,298,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Chicago Partners Investment Group LLC lifted its position in Amgen by 8.6% during the third quarter. Chicago Partners Investment Group LLC now owns 7,518 shares of the medical research company's stock worth $3,302,000 after acquiring an additional 596 shares during the last quarter. 3Chopt Investment Partners LLC boosted its holdings in shares of Amgen by 83.5% during the third quarter. 3Chopt Investment Partners LLC now owns 2,989 shares of the medical research company's stock worth $1,260,000 after acquiring an additional 1,360 shares during the period. Rakuten Investment Management Inc. bought a new stake in shares of Amgen during the third quarter worth approximately $60,952,000. Investment Insight Wealth Management LLC grew its position in shares of Amgen by 8.4% in the third quarter. Investment Insight Wealth Management LLC now owns 682 shares of the medical research company's stock valued at $287,000 after purchasing an additional 53 shares during the last quarter. Finally, Provenance Wealth Advisors LLC grew its position in shares of Amgen by 1,319.5% in the third quarter. Provenance Wealth Advisors LLC now owns 7,367 shares of the medical research company's stock valued at $3,105,000 after purchasing an additional 6,848 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Insider Activity at Amgen

In other news, SVP Rachna Khosla sold 2,000 shares of Amgen stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00. Following the sale, the senior vice president directly owned 6,404 shares of the company's stock, valued at approximately $2,642,098.28. This trade represents a 23.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.85% of the company's stock.

Amgen Price Performance

AMGN stock opened at $460.28 on Friday. The stock has a market cap of $248.84 billion, a price-to-earnings ratio of 26.70, a P/E/G ratio of 3.47 and a beta of 0.43. The company has a debt-to-equity ratio of 3.60, a current ratio of 1.48 and a quick ratio of 1.13. The company has a 50 day simple moving average of $421.96 and a 200 day simple moving average of $377.55. Amgen Inc. has a 1 year low of $312.39 and a 1 year high of $483.99.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share for the quarter, beating analysts' consensus estimates of $5.79 by $0.66. The firm had revenue of $10.37 billion for the quarter, compared to analyst estimates of $10.07 billion. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The company's quarterly revenue was up 8.5% on a year-over-year basis. During the same quarter last year, the business posted $5.64 earnings per share. Research analysts anticipate that Amgen Inc. will post 23.19 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Friday, November 20th. Amgen's dividend payout ratio is presently 62.65%.

Analyst Ratings Changes

Several analysts recently weighed in on AMGN shares. Guggenheim lifted their price target on Amgen from $378.00 to $435.00 and gave the stock a "neutral" rating in a report on Thursday. Barclays upped their price objective on Amgen from $380.00 to $400.00 and gave the company an "equal weight" rating in a report on Wednesday, October 21st. William Blair reaffirmed an "outperform" rating on shares of Amgen in a report on Wednesday. UBS Group increased their price objective on Amgen from $470.00 to $530.00 and gave the stock a "buy" rating in a research report on Wednesday. Finally, Scotiabank lifted their target price on Amgen from $500.00 to $530.00 and gave the stock a "sector outperform" rating in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, seventeen have assigned a Hold rating and three have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $419.10.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: A large real-world study found Repatha reduced fatal or nonfatal heart-attack risk by 20% versus ezetimibe among people with heart disease. The results could support Repatha’s growth and use in treatment decisions. Repatha real-world study
• Positive Sentiment: Amgen also reported stronger third-quarter results and raised its 2026 outlook. Recent coverage highlights growth in key products and pipeline prospects, including IMDELLTRA and MariTide. Q3 earnings call highlights
• Neutral Sentiment: Analyst changes are mixed: Leerink raised its target to $464 and kept a market-perform rating, while Guggenheim raised its target to $435 but maintained a neutral rating. These targets suggest limited upside or downside around the recent share level. Leerink Partners rating Guggenheim rating
• Negative Sentiment: Despite the earnings beat and higher guidance, declines in Prolia and Xgeva—amid biosimilar competition—remain a concern. That pressure may be weighing on sentiment and offsetting positive news about growth products and the pipeline. Q3 results and product declines

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company's products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.